Walid Abi-Saab Sells 1,434 Shares of uniQure (NASDAQ:QURE) Stock

uniQure N.V. (NASDAQ:QURE) insider Walid Abi-Saab sold 1,434 shares of the business’s stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $46.86, for a total value of $67,197.24. Following the sale, the insider owned 168,235 shares of the company’s stock, valued at approximately $7,883,492.10. The trade was a 0.85% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Walid Abi-Saab also recently made the following trade(s):

• On Friday, May 8th, Walid Abi-Saab sold 45,000 shares of uniQure stock. The stock was sold at an average price of $25.06, for a total transaction of $1,127,700.00.

uniQure Trading Down 1.9%

Shares of uniQure stock opened at $45.17 on Thursday. The company has a fifty day simple moving average of $29.56 and a 200-day simple moving average of $23.58. uniQure N.V. has a 12-month low of $8.73 and a 12-month high of $71.50. The company has a current ratio of 10.40, a quick ratio of 10.40 and a debt-to-equity ratio of 0.33. The stock has a market cap of $2.85 billion, a price-to-earnings ratio of -12.98 and a beta of 0.90.

uniQure (NASDAQ:QURE) last announced its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) EPS for the quarter, topping the consensus estimate of ($0.88) by $0.03. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. The firm had revenue of $3.56 million for the quarter, compared to analyst estimates of $5.21 million. On average, equities analysts forecast that uniQure N.V. will post -3.63 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently issued reports on QURE shares. Leerink Partners upped their target price on uniQure from $36.00 to $70.00 and gave the company an “outperform” rating in a research report on Thursday, June 18th. Cantor Fitzgerald raised uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 price target on the stock in a research report on Wednesday, June 17th. HC Wainwright boosted their price objective on uniQure from $50.00 to $80.00 and gave the company a “buy” rating in a research note on Monday. Stifel Nicolaus set a $28.00 price objective on uniQure in a report on Tuesday, May 5th. Finally, The Goldman Sachs Group raised their target price on shares of uniQure from $14.00 to $46.00 and gave the stock a “neutral” rating in a research report on Thursday, June 18th. Twelve equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $64.17.

Key Stories Impacting uniQure

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating on uniQure and kept its $80 price target, while raising earnings estimates across several future periods, including FY2026, FY2027, FY2028, FY2029, and FY2030, which suggests growing confidence in the company’s longer-term outlook.
• Positive Sentiment: Analysts also highlighted a technical breakout: uniQure now trades above a golden cross and a key support level, a setup that can attract momentum-oriented traders and may be helping the shares rebound.
• Neutral Sentiment: HC Wainwright slightly improved estimates for near-term quarters such as Q2 2026, Q3 2026, Q4 2026, and Q1 2027, but the company is still expected to post losses in those periods, so the revisions are supportive but not a sign of near-term profitability.
• Negative Sentiment: Insider Walid Abi-Saab sold 1,434 shares at $46.86, adding to a prior larger sale in May. While the sale was small relative to his total holdings, insider selling can sometimes weigh on sentiment.

Institutional Investors Weigh In On uniQure

A number of hedge funds have recently added to or reduced their stakes in QURE. Torren Management LLC acquired a new position in uniQure during the 4th quarter worth approximately $28,000. IFP Advisors Inc purchased a new stake in shares of uniQure in the fourth quarter valued at approximately $48,000. Smartleaf Asset Management LLC purchased a new stake in shares of uniQure in the fourth quarter valued at approximately $48,000. CIBC Private Wealth Group LLC acquired a new position in uniQure during the third quarter worth $50,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in uniQure by 42.7% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,027 shares of the biotechnology company’s stock worth $72,000 after acquiring an additional 906 shares during the period. Institutional investors and hedge funds own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.